Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

CAPS Rating: 4 out of 5

The Company is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases.


Player Avatar genedom (97.67) Submitted: 9/12/2013 3:07:59 AM : Underperform Start Price: $3.72 RIGL Score: +25.50

A biotech with a bad luck. No one has faith anymore.

Featured Broker Partners